Novo Nordisk's Rybelsus Now First Oral GLP-1 RA In Europe With Proven Heart Health Impact

benzinga.com/news/health-care/25/09/47675095/novo-nordisks-rybelsus-now-first-oral-glp-1-ra-in-europe-with-proven-heart-health-impact

On Monday, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) approved an update to Novo Nordisk A/S‘ (NYSE:NVO) Rybelsus (oral semaglutide) label to reflect the cardiovascular benefits seen in the SOUL trial.
SOUL was a phase 3b trial carried out…

This story appeared on benzinga.com, 2025-09-15 17:23:07.
The Entire Business World on a Single Page. Free to Use →